These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1423243)

  • 1. Expression of p43 in breast cancer tissue, correlation with prognostic parameters.
    Rosen HR; Moroz C; Reiner A; Stierer M; Svec J; Reinerova M; Schemper M; Jakesz R
    Cancer Lett; 1992 Oct; 67(1):35-45. PubMed ID: 1423243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.
    Rosen HR; Moroz C; Reiner A; Reinerova M; Stierer M; Svec J; Schemper M; Jakesz R
    Breast Cancer Res Treat; 1992; 24(1):17-26. PubMed ID: 1463868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of placental ferritin (PLF)-positive lymphocytes in women in early stages of breast cancer.
    Rosen HR; Stierer M; Göttlicher J; Wolf H; Weber R; Vogl E; Eibl M
    Int J Cancer; 1992 Sep; 52(2):229-33. PubMed ID: 1521910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p43 associated placental isoferritin (PLF) correlates inversely with cell growth in breast cancer cell lines MCF-7 and T47-D.
    Reinerová MH; Rosen HR; Veselovská Z; Stierer M; Svec J
    Neoplasma; 1993; 40(3):147-51. PubMed ID: 8350961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the immunoregulator p43-placental isoferritin in the human embryo and fetus.
    Maymon R; Jauniaux E; Greenwold N; Traub L; Moroz C
    Mol Hum Reprod; 2000 Sep; 6(9):843-8. PubMed ID: 10956557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced expression of the immunoregulator, p43-placental isoferritin, in Down's syndrome placentae and fetal kidneys.
    Maymon R; Jauniaux E; Moroz C
    Mol Hum Reprod; 2002 Dec; 8(12):1125-8. PubMed ID: 12468646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive activity of lymphocyte mitogenesis by breast cancer-associated p43.
    Reinerová M; Veselovská Z; Ausch C; Rosen HR
    Neoplasma; 1996; 43(6):363-6. PubMed ID: 8996559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of p43 placental isoferritin in human maternal-fetal tissue interface.
    Maymon R; Jauniaux E; Greenwold N; Moroz C
    Am J Obstet Gynecol; 2000 Mar; 182(3):670-4. PubMed ID: 10739528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of lymphocyte mitogenesis by breast cancer-associated p43.
    Rosen HR; Ausch C; Reiner G; Reinerova M; Svec J; Tüchler H; Schiessel R; Moroz C
    Cancer Lett; 1994 Jul; 82(1):105-11. PubMed ID: 8033063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of women with early breast cancer by analysis of p43-positive lymphocytes.
    Auerbach L; Hellan M; Stierer M; Rosen AC; Ausch C; Obwegeser R; Kubista E; Wolf G; Rosen HR; Panzer S
    Br J Cancer; 1999 May; 80(5-6):874-8. PubMed ID: 10360668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished expression of placental isoferritin p43 component in first trimester abnormal pregnancies.
    Jauniaux E; Maymon R; Greenwold N; Hustin J; Moroz C
    Placenta; 2000 May; 21(4):408-11. PubMed ID: 10833377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody CM-H-9 detects circulating placental isoferritin in the serum of patients with visceral metastases of breast cancer.
    Rosen HR; Flex D; Stierer M; Moroz C
    Cancer Lett; 1991 Aug; 59(2):145-51. PubMed ID: 1884372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines.
    Shterman N; Kupfer B; Moroz C
    Pathobiology; 1991; 59(1):19-25. PubMed ID: 2043266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of cytosolic p53 protein in breast cancer.
    Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
    Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of isoferritin level in breast cancer tissue and serum].
    Cai G; Zeng W; Chen P; Lü S; Zhao Y; Yang H
    Hua Xi Yi Ke Da Xue Xue Bao; 1994 Mar; 25(1):15-7. PubMed ID: 8070763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferritin.
    Moroz C; Shterman N; Kupfer B; Ginzburg I
    Proc Natl Acad Sci U S A; 1989 May; 86(9):3282-5. PubMed ID: 2654941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
    Gasparini G; Toi M; Gion M; Verderio P; Dittadi R; Hanatani M; Matsubara I; Vinante O; Bonoldi E; Boracchi P; Gatti C; Suzuki H; Tominaga T
    J Natl Cancer Inst; 1997 Jan; 89(2):139-47. PubMed ID: 8998183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of cell surface antigens induced by placental isoform of ferritin in human carcinoma cell lines.
    Sedlak J; Reinerova M; Hunakova L; Ausch C; Chorvath B; Rosen H; Moroz C
    Cancer Lett; 1995 Jul; 94(1):101-6. PubMed ID: 7542560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppression by breast cancer associated p43-effect of immunomodulators.
    Rosen HR; Ausch C; Reiner G; Reinerova M; Svec J; Tüchler H; Schiessel R; Moroz C
    Breast Cancer Res Treat; 1996; 41(2):171-6. PubMed ID: 8944335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.